

HUMAN PLASMA FIBRONECTIN PURIFIED PROTEIN

CATALOG NUMBER: FC010 QUANTITY: 1 mg

LOT NUMBER: CONCENTRATION: 1 mg/mL

DESCRIPTION: Human fibronectin (hFN) is suitable for use as an attachment factor in the propagation of cells

in vitro when used to coat cell culture surfaces, including plasticware, glassware, and

microcarrier beads.

SOURCE: Human donor plasma

PURITY: Approximately 95%, as determined by SDS-PAGE. A double band of 220 kDa is present

under reduced conditions. hFN is purified by affinity chromatography on gelatin agarose, followed by chromatography on heparin-agarose. Plasma from donors has been screened,

and shown to be negative for HIV, HTLV, Hepatitis B and C.

APPLICATIONS: Immunochemical standard

Cell attachment and proliferation assays on human endothelial cells, human keratinocytes and

human dermal fibroblasts

Suggested Procedure for Coating Cell Cultureware

1. Determine the amount of HFN needed to coat culture vessels by multiplying the total surface area (cm²) by the desired concentration (µg/mL) of HFN. Recommended amount

is 2-10 μ g/cm².

2. Wet the surface of each culture vessel to be coated with a minimum amount of sterile

balanced salt solution (serum and protein free) required to cover the entire area.

3. Introduce the proper CO₂ atmosphere, if required.

4. Add the calculated amount of HFN to each culture vessel.

5. Allow HFN to adsorb to the surface of the vessel for 5-20 minutes.

6. Remove residual balanced salt solution before proceeding with standard cell culture

procedures.

Optimal working dilutions must be determined by end user.

PRESENTATION: Liquid in 150 mM NaCl, 10 mM sodium phosphate, pH 7.5, sterile filtered, containing no

preservatives.

STORAGE/HANDLING: Maintain at 2-8° C for up to 6 months from date of receipt. Do not freeze.

REFERENCES: Kim, JE *et al.* (2002). Molecular Properties of Wild-Type and Mutant βIG-H3 Proteins. *Invest*

Ophthalmol Vis Sci 43(3): 656-661.

Scarpa, S. et al. (2002). Retinoic acid inhibits fibronectin and laminin synthesis andcell migration of

human pleural mesothelioma in vitro. Oncology Reports 9: 205-209.

Marchenko, G. N. *et al.* (2001). Characterization of matrix metalloproteinase-26, a novel metalloprotinase widely expressed in cancer cells of epithelial origin. *Biochem. J.* **356**: 705-718.

Ni, H, et al (1998). Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied





conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. *J Biol Chem* **273**: 7981-7.

Ruoslahti E. *et al.* (1981). Comparative studies on amniotic fluid and plasma fibronectins. *Biochem. J* **193**: 295-299.

Engvall E and Ruoslahti E. (1977). Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. *Int J Cancer.* **20**: 1-5.

Important Note:

During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μ L or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container's cap.

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

©2002 - 2010: Millipore Corporation. All rights reserved. No part of these works may be reproduced in any form without permission in writing